Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 17 February 2015 | By Alexander Gaffney, RAC,
Despite rumors of its demise, the US Food and Drug Administration’s (FDA) controversial plan to allow generic drug companies to update their labels to reflect new and emerging safety information isn’t dead—not yet, at least.
As Regulatory Focus has extensively reported in the past, FDA has long been interested in making it easier for all drug companies—not just innovative manufacturers—to update the safety labeling on drug products.
Read our Regulatory Explainer on the regulation of generic drug labeling here.
At present, federal regulations prohibit a generic drug product from bearing any labeling not also borne by the product it references (i.e. the product to which it is generic).
In theory, this is meant to ensure a generic drug is not seen as more (or less) safe or effective than its innovative product.
In practice, however, this has resulted in some negative effects. For example, some generic drug companies have been unable to update their labels to reflect new adverse events, as either the brand-name drug manufacturer has failed to push for an update, or sometimes because the owner of the reference listed drug (RLD) no longer exists.
In response, FDA unveiled a new proposed rule in November 2013, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products.
The rule would permit a sponsor of a generic drug to immediately issue a labeling change for any safety-related change, starting a process intended to allow differences to exist between the generic drug, the RLD and other approved generic drugs on a "temporary basis."
The labeling change application to FDA would need to contain information such as the basis for the labeling change and available data to support the change, such as adverse event data, published literature or epidemiologic studies.
Since the release of FDA’s proposed rule, the agency has encountered significant pushback.
Generic drug companies strongly oppose the rule, and have said it could open them up to billions of dollars in annual legal liabilities and increased pharmacovigilance monitoring costs. Various legislators have called into question the legality of the proposed rule, saying the Hatch-Waxman Act of 1984 does not permit the agency to authorize differences in labeling.
For a complete breakdown of the reaction to FDA’s proposed rule, please see the section “How Has the Pharmaceutical Industry Reacted to FDA's Proposed Labeling Rule?” of our Regulatory Explainer.
While FDA has steadfastly defended both its right to and reasons for promulgating the proposed rule, it nevertheless announced in December 2014 that it would delay finalizing the rule until 2015, which some industry watchers interpreted as FDA’s attempt to quietly table the rule.
But the proposed rule isn’t dead, and might just be preparing to emerge in a different form.
In a Federal Register notice published on 17 February 2015, FDA said it was reopening the comment period for the proposed regulation in light of both the significant amount of interest in FDA’s proposal and the emergence of alternate proposals put forth and endorsed by the generic pharmaceutical industry.
Such proposals might allow FDA to still accomplish its policy goal of providing additional safety information, but would have the added benefit of avoiding litigation by the generic pharmaceutical industry against FDA over the rule.
The agency, it said, plans to soon “hold a public meeting at which any stakeholders may present or comment on the proposed rule or any alternative proposals intended to improve communication of important newly acquired drug safety information to health care professionals and the public.”
In addition to the public meeting, FDA said the comment period on the proposed rule will open again from 18 February through 27 April 2015. Comments may focus on either FDA’s proposed rule or “alternative proposals presented during the public meeting,” the agency said.
Federal Register Notice
Tags: Generic Drug Labeling, Generic Drug Labeling Rule, Proposed Rule
Regulatory Focus newsletters
All the biggest regulatory news and happenings.